对治疗干预的ESKAPE病原体的基因酶的洞察力
Deepansh Mody1, Priyanka Joshi2, Monika Antil2
1Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Canada.
Cardiovascular & hematological agents in medicinal chemistry
|October 15, 2024
概括
耐多药ESKAPE病原体威胁全球健康. 准细菌激酶对生存和毒性至关重要,为开发针对这些超级细菌的新型抗微生物药物提供了一个有希望的战略.
科学领域:
- 微生物学 微生物学
- 生物化学 生物化学
- 药物发现 药物发现 药物发现
背景情况:
- 逃生病原体是医院感染的主要原因,对现有的抗生素表现出耐药性.
- 多种药物耐药性的出现需要开发针对重要细菌途径的新型抗菌战略.
- 细菌激酶在病原体的生存,毒性和抗生素耐药性方面发挥着至关重要的作用.
研究的目的:
- 审查参与ESKAPE病原体毒性和药物耐药性的效应体细菌激酶.
- 阐明激酶在生物膜形成中的作用,这是ESKAPE病变发生的关键因素.
- 总结目前针对ESKAPE激酶的治疗开发工作.
主要方法:
- 对细菌基因组和毒性因子研究的文献综述.
- 分析与宿主免疫逃避和抗生素耐药性相关的生化途径.
- 对正在进行的开发抗微生物治疗用激酶抑制剂的研究进行调查.
主要成果:
- 细菌激酶对于ESKAPE病原体的生存,免疫逃避和生物膜形成至关重要.
- 针对特定的激酶可以破坏关键的毒性机制,克服耐药性.
- 目前正在研究针对ESKAPE激酶的几种治疗方法.
结论:
- 细菌激酶是新型抗微生物点的一个有前途的类别.
- 对ESKAPE激酶通路的进一步研究可以指导开发急需的治疗方法.
- 抑制ESKAPE激酶可能提供一种可行的策略来对抗多药耐药性感染.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
MAPK Signaling Cascades
5.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K
Amplifying Signals via Enzymatic Cascade
8.3K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.3K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


